UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 27, 2005
Anika Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
Massachusetts |
|
000-21326 |
|
04-314-5961 |
|
(State or other
jurisdiction of |
|
Commission file number |
|
(I.R.S. Employer |
|
|
|
|
|
|
|
160 New Boston Street, Woburn, MA 01801 |
||||
|
(Address of principal executive offices) (Zip code) |
||||
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: 781-932-6616 |
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
(Former name or former address, if changed since last report) |
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On July 27, 2005, Anika Therapeutics, Inc. issued a press release announcing its financial results for the second quarter of 2005. The full text of the press release is furnished as Exhibit 99.1 hereto.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
99.1 Press Release of Anika Therapeutics, Inc. dated July 27, 2005.
[Remainder of page left blank intentionally]
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be filed on its behalf by the undersigned hereunto duly authorized.
|
|
Anika Therapeutics, Inc. |
|||
|
|
|
|
||
|
Dated: July 27, 2005 |
By: |
|
/s/ Kevin W. Quinlan |
|
|
|
|
|
Kevin W. Quinlan |
|
|
|
|
|
Chief Financial Officer |
|
3
Exhibit Index
99.1 Press Release of Anika Therapeutics, Inc. dated July 27, 2005.
4